Results 31 to 40 of about 145,743 (338)
Molecules, 2023 Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu +12 more
doaj +1 more source
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
Scientific Reports, 2021 Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi +4 more
doaj +1 more source
HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
BIO Integration, 2023 Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang +9 more
doaj +1 more source
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
openaire +3 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Umbreen Hafeez +3 more
openaire +4 more sources
Strain prioritization and genome mining for enediyne natural products [PDF]
, 2016 The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine, and yet only 11 enediynes have been structurally characterized to date.
Ben Shen +18 more
core +2 more sources
Site-selective protein modification via disulfide rebridging for fast tetrazine/trans-cyclooctene bioconjugation [PDF]
, 2020 An inverse electron demand Diels–Alder reaction between tetrazine and trans-cyclooctene (TCO) holds great promise for protein modification and manipulation.
Chudasama, V. +6 more
core +1 more source
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
Pharmaceuticals, 2021 In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain +8 more
doaj +1 more source
An Immunosuppressive Antibody–Drug Conjugate [PDF]
Journal of the American Chemical Society, 2015 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E +13 more
openaire +4 more sources